Intranasal Oxytocin for Obesity.
Plessow F, Kerem L, Wronski ML, Asanza E, O'Donoghue ML, Stanford FC, Eddy KT, Holmes TM, Misra M, Thomas JJ, Galbiati F, Muhammed M, Sella AC, Hauser K, Smith SE, Holman K, Gydus J, Aulinas A, Vangel M, Healy B, Kheterpal A, Torriani M, Holsen LM, Bredella MA, Lawson EA.
Plessow F, et al. Among authors: holsen lm.
NEJM Evid. 2024 May;3(5):EVIDoa2300349. doi: 10.1056/EVIDoa2300349. Epub 2024 Apr 23.
NEJM Evid. 2024.
PMID: 38815173
Clinical Trial.
Key secondary end points included change in body composition (total fat mass [g], abdominal visceral adipose tissue [cm(2)], and liver fat fraction [proportion; range, 0 to 1; higher values indicate a higher proportion of fat]), and resting energy expenditure (kcal/day; adjusted …
Key secondary end points included change in body composition (total fat mass [g], abdominal visceral adipose tissue [cm(2)], and liver fat f …